179333-63-2Relevant academic research and scientific papers
TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR
-
Page/Page column 44, (2012/02/02)
The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase
Kumar, Sanjeev,Jaller, Daniel,Patel, Bhumika,LaLonde, Judith M.,DuHadaway, James B.,Malachowski, William P.,Prendergast, George C.,Muller, Alexander J.
experimental part, p. 4968 - 4977 (2009/07/11)
Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. With the goal of developing more potent IDO in
PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF
-
Page/Page column 58, (2010/02/14)
The invention relates to novel phenylthioacetic acid derivatives of formula (I), to a method for the production thereof, to the use thereof for the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prevention of cardiovascular diseases, in particular dyslipidaemia and arteriosclerosis. The compounds act as modulators for the PRAR-alpha receptor.
Monocyclic, substituted imidazoles as glycosidase inhibitors
Magdolen, Peter,Vasella, Andrea
, p. 2454 - 2469 (2007/10/03)
A range of 4-monosubstituted and 2,4-disubstituted 1H-imidazoles and 1H-imidazole-1-ethanols (R-C(4): CH2CH2Ph, CHOHCH 2Ph, Ph, or Me; R-C(2): CH2OH, CHOHCH2OH, CN, or CH2NHAc) were prepare
Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
-
, (2008/06/13)
Disclosed are compounds of the formula: wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorganic substitutents which may togther form ring structutes; m is zero, one or two; and R5 and R6 are are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.
